読み込み中
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
通常取引
$8.8562
−$0.0238 · -0.27%
日中の時刻はETです。市場データは遅延する場合があります。
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
日中レンジ
現在 $8.8562
52週レンジ
現在 $8.8562
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
37
割高
センチメント
44
まちまち
リスク
76
高リスク
モメンタム
53
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
日中レンジ
現在 $8.8562
52週レンジ
現在 $8.8562
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | 200万 USD | — | — |
| 粗利益 | — | — | 200万 USD | — | — |
| 研究開発 | 3905.4万 USD | 3844.4万 USD | 1977.7万 USD | 2491.9万 USD | 1934万 USD |
| 販売・一般管理 | 1783.5万 USD | 1601万 USD | 1296.3万 USD | 613.6万 USD | 437.9万 USD |
| 営業費用 | 5688.9万 USD | 5445.4万 USD | 3274万 USD | 3105.5万 USD | 2371.9万 USD |
| 受取利息 | 585.1万 USD | 888.7万 USD | 286万 USD | 55.3万 USD | 2.6万 USD |
| 減価償却費と償却費 | — | — | — | 13万 USD | — |
| 営業利益 | −5688.9万 USD | −5445.4万 USD | −3074万 USD | −3105.5万 USD | −2371.9万 USD |
| 純利益 | −5103.8万 USD | −4556.7万 USD | −2787.6万 USD | −3049.9万 USD | −2444.2万 USD |
会社概要が更新されました 2026年10月8日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$20.00
上昇余地（125.83%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1909.62万0.00%2.3兆 USD0.03%$379.12-0.50%
iShares Russell 2000 ETFIWM1376.55万0.02%785.63億 USD0.19%$276.91-0.29%
State Street SPDR S&P Biotech ETFXBI1152.94万0.11%100.75億 USD0.35%$149.08-0.77%
Vanguard Extended Market ETFVXF684.89万0.01%954億 USD0.05%$232.72-0.33%
iShares Biotechnology ETFIBB385.73万0.04%104.01億 USD0.44%$200.05-1.62%
iShares Russell 2000 Growth ETFIWO374.55万0.03%142.49億 USD0.24%$352.48-0.81%
Vanguard Russell 2000 ETFVTWO346.32万0.02%180億 USD0.06%$111.84-0.33%
Dimensional - US Small Cap ETFDFAS232.73万0.01%336.6億 USD0.31%$78.01+0.12%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
